The purpose of this study is to collect data from patients by social media and self-report on the adverse events and outcomes happened with patients with extranodal natural killer/T-cell lymphoma, nasal type, who are treated outside of clinical trials in China.
Extranodal natural killer/T-cell lymphoma, nasal type, is a rare subtype of non-Hodgkin lymphoma with relatively high incidence in China. L-asparaginase based chemotherapy are widely used with Chinese patients and has been reported to improve overall response and prolonged the long-term survival in some clinical trials with very limited patients. However, most patients were treated out of clinical trials in China. Therefore the real incidence of adverse events and treatment outcomes are largely unknown. This study is designed to evaluate the incidence of adverse events and treatment outcomes by social media-based (www.house086.com, www.wechat.com) self-report from patients who are treated out of clinical trials.
Study Type
OBSERVATIONAL
Enrollment
665
Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
Lymphoma House086
Beijing, Beijing Municipality, China
Xinhua Hospital
Shanghai, Shanghai Municipality, China
overall survival
The overall survial time of patients will be measured since the initiation of treatment to death of any reason.
Time frame: 2-year
Treatment-Related Adverse Events as Assessed by CTCAE v4.0
Chemotherapy-related and radiotherapy-related toxicities and adverse events will be collected and graded by NCI CTCAE v4.0 criteria.
Time frame: Day 1 of each course of chemotherapy and radiotherapy then every 3 months for 2 years
Progression free survival
Progression free survival time is defined as the time from the initiation of treatment to the date on which disease "progresses" or the date on which the patient dies, from any cause.
Time frame: 2-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.